** Hong Kong shares of vaccine producer CanSino Biologics Inc 6185.HK jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain
** Stock on track for the biggest one-day pct gain since Nov. 11, 2024
** Shanghai-listed stock 688185.SS climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024
** CanSino said China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years
** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co
** Hong Kong's healthcare index .HSCIH rises 1.4%, Hang Seng Index .HSI surges 1.7%
** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。